vTv Therapeutics Announces Completion of Enrollment in Phase 3 CATT1 Study of Cadisegliatin in Type 1 Diabetes (T1D)
vTv Therapeutics completed enrollment in its Phase 3 CATT1 study of cadisegliatin as adjunctive therapy in type 1 diabetes, with 166 patients randomized. CATT1 (NCT06334133) is a randomized, double-blind, placebo-controlled six-month trial testing 800 mg once- and twice-daily dosing, with a primary endpoint of level 2 and level 3 hypoglycemic events.
Key figures
- Drug Name
- cadisegliatin (TTP399)
- Phase Of Trial
- Phase 3
- Treatment arms
- ["cadisegliatin 800 mg once daily","cadisegliatin 800 mg twice daily","placebo"]
- Patients randomized
- 166
- Study duration months
- 6
- Topline results timing
- mid 2027
- T1d prevalence worldwide
- 9.5 million
- T1d prevalence 2040 projection
- 14.7 million
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.